FY2029 Earnings Forecast for ONCY Issued By HC Wainwright

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Stock analysts at HC Wainwright issued their FY2029 earnings estimates for Oncolytics Biotech in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $1.10 for the year. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.29) per share.

ONCY has been the subject of a number of other research reports. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th. Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Stock Up 3.2 %

Shares of NASDAQ ONCY opened at $0.72 on Tuesday. Oncolytics Biotech has a twelve month low of $0.67 and a twelve month high of $1.53. The firm has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $0.97. The company has a market capitalization of $57.37 million, a PE ratio of -2.66 and a beta of 1.24.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Vantage Point Financial LLC purchased a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 29,744 shares of the company’s stock, valued at approximately $27,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.